Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2C | Q5R387 | 2/20 | 0.43 |
| ▸ | PLA2G2D | Q9UNK4 | 1/20 | 0.39 |
| ▸ | P2RY10 | O00398 | 9/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 5/20 | 0.38 |
| ▸ | LPAR6 | P43657 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.36 |
| ▸ | LPAR4 | Q99677 | 1/20 | 0.36 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.36 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.36 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | GPR174 | Q9BXC1 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17144721 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL19410782 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL226745 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL3963403 | 1.00 | PLA2G2C (0.43) | PLA2G2CPLA2G2DP2RY10GPR34LPAR6 | |
| SCHEMBL18262003 | 0.94 | P2RY10 (0.44) | P2RY10GPR34LPAR6LPAR1LPAR4 | |
| SCHEMBL969822 | 0.94 | P2RY10 (0.44) | P2RY10GPR34LPAR6LPAR1LPAR4 | |
| SCHEMBL7571747 | 0.94 | P2RY10 (0.44) | P2RY10GPR34LPAR6LPAR1LPAR4 | |
| SCHEMBL7570925 | 0.91 | S1PR1 (0.47) | P2RY10GPR34 | |
| SCHEMBL7203823 | 0.91 | PLA2G2C (0.36) | PLA2G2CPLA2G2D | |
| SCHEMBL5312425 | 0.87 | ALDH1A1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10973935-B2 | Stabilized nanobubbles for diagnostic and therapeutic applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2021-04-13 | — | — | US | claimed |
| US-20200061220-A1 | STABILIZED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CASE WESTERN UNIVERSITY | 2020-02-27 | — | — | US | claimed |
| US-10357575-B2 | Stabilized nanobubbles for diagnostic and therapeutic applications | CASE WESTERN RESERVE UNIVERSITY (US) | 2019-07-23 | — | — | US | claimed |
| US-20170095420-A1 | SURFACE CROSS-LINKED LIPIDIC PARTICLES, METHODS OF PRODUCTION AND USES THEREFOR | Maria I. C. Gyongyossy-Issa (CA) | 2017-04-06 | — | — | US | claimed |
| US-20170095421-A1 | SYNTHETIC PLATELETS | Maria I. C. Gyongyossy-Issa (CA) | 2017-04-06 | — | — | US | claimed |
| CN-105658204-A | Method for physically encapsulating, in hydrogel particle, liposome containing active ingredient, and cosmetic composition containing same | 华斯泰株式会社 | 2016-06-08 | — | — | CN | claimed |
| US-20140147390-A1 | STABILIZED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2014-05-29 | — | — | US | claimed |
| EP-1897536-B1 | Surface cross-linked lipidic particles, methods of production and uses therefor | GYONGYOSSY ISSA MARIA I C (CA) | 2012-06-27 | — | — | EP | claimed |
| EP-1935409-B1 | Synthetic platelets | GYONGYOSSY ISSA MARIA I C (CA) | 2012-06-27 | — | — | EP | claimed |
| WO-2012040710-A2 | STABILIZED NANOBUBBLES FOR DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | CASE WESTERN RESERVE UNIVERSITY (US) | 2012-03-29 | — | — | WO | claimed |
| WO-2009129395-A1 | CATIONIC LIPIDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | WO | claimed |
| EP-4746853-A1 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-12551527-B2 | Drug delivery systems for treatment of infections | WAYNE STATE UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| WO-2025021835-A9 | A LIPID DRUG DELIVERY SYSTEM FOR INCREASED ENDOSOMAL ESCAPE | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-11-06 | — | — | WO | disclosed |
| US-12460192-B2 | Lipid-encapsulated dual-cleaving endonuclease for DNA and gene editing | SPECIFIC BIOLOGICS INC. (CA) | 2025-11-04 | — | — | US | disclosed |
| WO-2006136963-A2 | AIRWAY ADMINISTRATION OF SITE-INACTIVATED FVIIA IN INFLAMMATORY CONDITIONS AFFECTING THE RESPIRATORY TRACT | DRUGRECURE APS (DK) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006104639-A2 | DEVICE COMPRISING ARRAY OF MICRO-OR NANO-RESERVOIRS | STANFORD UNIVERSITY (US) | 2006-10-05 | — | — | WO | disclosed |
| EP-1594459-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2005-11-16 | — | — | EP | disclosed |
| US-20040225077-A1 | Drug delivery from rapid gelling polymer composition | ANGIOTECH INTERNATIONAL AG (CH) | 2004-11-11 | — | — | US | disclosed |
| WO-2004060346-A2 | DRUG DELIVERY FROM RAPID GELLING POLYMER COMPOSITION | ANGIOTECH INTERNATIONAL AG (CH) | 2004-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551527-B2 | Drug delivery systems for treatment of infections | PHOSPHO1, PCTP, SGMS1 | PLA2G2C 348/4885PLA2G2D 2376/4885P2RY10 4745/4885 |
| US-20170095421-A1 | SYNTHETIC PLATELETS | SELPLG, SELP, PLTP | PLA2G2C 153/4885PLA2G2D 447/4885P2RY10 300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.